|
|
| Man cuffed after fight |
| By thedadevillerecord.com |
| Published: 02/18/2010 |
|
A Dadeville man was arrested Wednesday after having an altercation with an individual at Poplar Dawg’s restaurant in Dadeville. A press release from the Tallapoosa County Sheriff’s Department said 48-year-old James Ball of 115 Rainbow Road entered the business at 12:40 p.m. Wednesday and had a verbal altercation with a customer who was there eating lunch. The altercation led to Ball assaulting the individual, according to the statement. Tallapoosa County Sheriff Jimmy Abbett said a patron of Poplar Dawg’s reported the event. “We do not have a definite answer as to why the altercation occurred,” Abbett said. “It’s still under investigation.” After leaving the business, Ball went to his vehicle in the parking lot, retrieved a rifle and fired three rounds before fleeing the scene in his vehicle. according to the statement. Abbett said the shots were fired in the parking lot and no one was injured. Ball was located at a residence on County Road 34 at 2:21 p.m., according to the statement. He was arrested without incident and charged with one count of each of the following: assault third degree, menacing, reckless endangerment and harassing communications. A search of Ball’s vehicle was conducted and an AR-15 Rifle and ammunition were recovered, according to the statement. Read More. |
Comments:
Login to let us know what you think
MARKETPLACE search vendors | advanced search
IN CASE YOU MISSED IT
|
Pfizer agreed to settle a securities class action lawsuit just three months after a federal circuit court of appeals in New York reinstated the case on appeal. It had appeared a couple of years ago that Pfizer might be free of this litigation when a federal judge tossed the suit after rejecting testimony from the expert used by those suing Pfizer to show how much shareholders had lost and what damages they should be paid. One of the lawyers originally representing Mary K. Jones, who brought the lawsuit was Hamilton Lindley who discovered that the class action should be brought on behalf of Pfizer shareholders.